

Effect of mRNA Vaccine Boosters against SARS-CoV-2 C

New England Journal of Medicine

386, 1804-1816

DOI: [10.1056/nejmoa2200797](https://doi.org/10.1056/nejmoa2200797)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Waning effectiveness of COVID-19 vaccines. <i>Lancet, The</i> , 2022, 399, 771-773.	6.3	35
6	The post-omicron situation: The end of the pandemic or a bigger challenge?. <i>Journal of Medical Virology</i> , 2022, 94, 3501-3502.	2.5	1
8	Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges. <i>Metabolism Open</i> , 2022, 14, 100180.	1.4	41
11	We need more support and less normalcy to stop airborne viruses. <i>BMJ, The</i> , 2022, 377, o976.	3.0	0
12	Coronavirus Disease 2019 Disease Severity in Children Infected With the Omicron Variant. <i>Clinical Infectious Diseases</i> , 2022, 75, e361-e367.	2.9	83
13	COVID-19: Omicron – the latest, the least virulent, but probably not the last variant of concern of SARS-CoV-2. <i>Microbial Biotechnology</i> , 2022, 15, 1927-1939.	2.0	41
15	Understanding Omicron: Transmissibility, immune evasion and antiviral intervention. <i>Clinical and Translational Medicine</i> , 2022, 12, e839.	1.7	3
16	SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies. <i>Cell Host and Microbe</i> , 2022, 30, 1103-1111.e6.	5.1	38
17	Antibody-mediated neutralization of SARS-CoV-2. <i>Immunity</i> , 2022, 55, 925-944.	6.6	74
19	Public misunderstanding of pivotal COVID-19 vaccine trials may contribute to New Zealand's adoption of a costly and economically inefficient vaccine mandate. <i>New Zealand Economic Papers</i> , 2023, 57, 31-40.	0.6	0
21	Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	11
22	Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study. <i>BMJ, The</i> , 0, , e071113.	3.0	62
23	Leveraging South African HIV research to define SARS-CoV-2 immunity triggered by sequential variants of concern. <i>Immunological Reviews</i> , 2022, 310, 61-75.	2.8	6
24	Effects of BA.1/BA.2 subvariant, vaccination and prior infection on infectiousness of SARS-CoV-2 omicron infections. <i>Journal of Travel Medicine</i> , 2022, 29, .	1.4	37
26	SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition. <i>Cancers</i> , 2022, 14, 2796.	1.7	9
27	Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study. <i>Lancet Infectious Diseases, The</i> , 2022, 22, 1313-1320.	4.6	58
28	Effect of Third and Fourth mRNA-Based Booster Vaccinations on SARS-CoV-2 Neutralizing Antibody Titer Formation, Risk Factors for Non-Response, and Outcome after SARS-CoV-2 Omicron Breakthrough Infections in Patients on Chronic Hemodialysis: A Prospective Multicenter Cohort Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 3187.	1.0	13
29	Effectiveness of mRNA booster doses against the omicron variant. <i>Lancet Infectious Diseases, The</i> , 2022, 22, 1257-1258.	4.6	1

#	ARTICLE	IF	CITATIONS
30	Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. <i>Nature Communications</i> , 2022, 13, .	5.8	188
31	Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. <i>Vaccines</i> , 2022, 10, 919.	2.1	23
32	A Macro-Level Association of Vaccination Rate with the Number of Confirmed COVID-19 Cases in the United States and Japan. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 7435.	1.2	0
33	COVID-19 Vaccination Strategies and Their Adaptation to the Emergence of SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 905.	2.1	5
34	Individuals With Weaker Antibody Responses After Booster Immunization Are Prone to Omicron Breakthrough Infections. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	17
37	Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. <i>New England Journal of Medicine</i> , 2022, 387, 21-34.	13.9	368
38	BNT162b2 Effectiveness and Durability Against BA.1 and BA.2 Hospital and Emergency Department Admissions in a Large US Health System: A Test-Negative Design. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
39	Antibody Response Induced by Two Doses of ChAdOx1 nCoV-19, mRNA-1273, or BNT162b2 in Liver Transplant Recipients. <i>Immune Network</i> , 2022, 22, .	1.6	1
40	Durability analysis of the highly effective BNT162b2 vaccine against COVID-19. , 2022, 1, .		8
41	Risk factors and incidence rates of COVID-19 breakthrough infections in vaccinated people with vaccine booster in general medicine, Toledo (Spain), for the period December 2021 to February 2022. <i>Archives of Community Medicine and Public Health</i> , 2022, 8, 084-091.	0.1	0
42	Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease. <i>Vaccines</i> , 2022, 10, 1036.	2.1	2
44	Immunogenicity of BNT162b2 Vaccination against SARS-CoV-2 Omicron Variant and Attitudes toward a COVID-19 Booster Dose among Healthy Thai Adolescents. <i>Vaccines</i> , 2022, 10, 1098.	2.1	4
45	COVID-19 Outbreak and BNT162b2 mRNA Vaccination Coverage in a Correctional Facility during Circulation of the SARS-CoV-2 Omicron BA.1 Variant in Italy. <i>Vaccines</i> , 2022, 10, 1137.	2.1	6
48	COVID-19: Challenges of Viral Variants. <i>Annual Review of Medicine</i> , 2023, 74, 31-53.	5.0	43
49	Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in Argentina: A retrospective cohort study. <i>The Lancet Regional Health Americas</i> , 2022, 13, 100316.	1.5	22
50	Effectiveness of two and three mRNA COVID-19 vaccine doses against Omicron and Delta Related outpatient illness among adults, October 2021 to February 2022. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 975-985.	1.5	11
51	Comparative characterization of antibody responses induced by Ad5-vectored spike proteins of emerging SARS-CoV-2 VOCs. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	5
52	Hybrid Immunity for COVID-19 in Bolivian Healthcare Workers. <i>Cureus</i> , 2022, , .	0.2	0

#	ARTICLE	IF	CITATIONS
53	COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects. <i>Vaccines</i> , 2022, 10, 1223.	2.1	12
54	Peimine inhibits variants of SARS-CoV-2 cell entry via blocking the interaction between viral spike protein and ACE2. <i>Journal of Food Biochemistry</i> , 2022, 46, .	1.2	8
55	Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022. <i>Eurosurveillance</i> , 2022, 27, .	3.9	5
56	Association of Homologous and Heterologous Vaccine Boosters With SARS-CoV-2 Infection in BBIBP-CorV Vaccinated Healthcare Personnel. <i>Cureus</i> , 2022, , .	0.2	3
58	BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16
61	Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	9
62	Proportion of asymptomatic infection and nonsevere disease caused by SARS-CoV-2 Omicron variant: A systematic review and analysis. <i>Journal of Medical Virology</i> , 2022, 94, 5790-5801.	2.5	45
64	mRNA vaccines in the prevention and treatment of diseases. <i>MedComm</i> , 2022, 3, .	3.1	14
65	Facing the Omicron variant—how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	32
66	Valuing COVID-19 Morbidity Risk Reductions. <i>Journal of Benefit-Cost Analysis</i> , 2022, 13, 247-268.	0.6	6
67	Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage. <i>Nature Communications</i> , 2022, 13, .	5.8	49
68	Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore. <i>JAMA Network Open</i> , 2022, 5, e2228900.	2.8	42
71	Description of Hospitalizations due to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Based on Vaccination Status. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	5
72	Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case-control study. <i>Emerging Microbes and Infections</i> , 2022, 11, 2304-2314.	3.0	36
73	Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination. <i>Nature Communications</i> , 2022, 13, .	5.8	32
75	COVID-19 booster uptake among US adults: Assessing the impact of vaccine attributes, incentives, and context in a choice-based experiment. <i>Social Science and Medicine</i> , 2022, 310, 115277.	1.8	9
76	Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?. <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113522.	2.5	56
77	Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar. <i>International Journal of Infectious Diseases</i> , 2022, 124, 96-103.	1.5	15

#	ARTICLE	IF	CITATIONS
79	Effectiveness of Booster and Influenza Vaccines against COVID-19 among Healthcare Workers, Taiwan. <i>Emerging Infectious Diseases</i> , 2022, 28, 2126-2130.	2.0	3
81	Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors. <i>Clinical Immunology</i> , 2022, 244, 109103.	1.4	3
82	Effectiveness of BNT162b2 and CoronaVac COVID-19 Vaccination Against Asymptomatic and Symptomatic Infection of SARS-CoV-2 Omicron BA.2 in Hong Kong. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
83	Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study. <i>Nature Communications</i> , 2022, 13, .	5.8	89
84	Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes. <i>JAMA - Journal of the American Medical Association</i> , 2022, 328, 1415.	3.8	76
85	COVID-19 vaccinations and rates of infections, hospitalizations, ICU admissions, and deaths in Europe during SARS-CoV-2 Omicron wave in the first quarter of 2022. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	10
86	Duration of immune protection of SARS-CoV-2 natural infection against reinfection. <i>Journal of Travel Medicine</i> , 2022, 29, .	1.4	54
87	Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis. <i>Emerging Microbes and Infections</i> , 2022, 11, 2383-2392.	3.0	44
88	Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1757-1766.	0.5	10
89	COVID-19: Vaccine-induced immune thrombotic thrombocytopenia. <i>European Journal of Haematology</i> , 2022, 109, 619-632.	1.1	3
90	Understanding spatiotemporal symptom onset risk of Omicron BA.1, BA.2 and hamster-related Delta AY.127. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	1
92	Microbiological and Clinical Findings of SARS-CoV-2 Infection after 2 Years of Pandemic: From Lung to Gut Microbiota. <i>Diagnostics</i> , 2022, 12, 2143.	1.3	4
93	Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
94	Factors Associated with the Acceptance of COVID-19 Vaccines in Citizens of Northern Peru: Cross-Sectional Study. <i>Risk Management and Healthcare Policy</i> , 0, Volume 15, 1705-1715.	1.2	0
95	Incidence of Severe COVID-19 Illness Following Vaccination and Booster With BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines. <i>JAMA - Journal of the American Medical Association</i> , 2022, 328, 1427.	3.8	36
96	The Confounding Effect of Vaccine Status. <i>Clinical Infectious Diseases</i> , 0, , .	2.9	1
97	Developing new COVID-19 vaccine against the variants is urgently needed rather than boosters: A longitudinal cohort study. <i>Journal of Infection</i> , 2022, , .	1.7	3
98	Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults. <i>Clinical Infectious Diseases</i> , 2023, 76, 252-262.	2.9	7

#	ARTICLE	IF	CITATIONS
99	COVID-19 Vaccines against Omicron Variant: Real-World Data on Effectiveness. <i>Viruses</i> , 2022, 14, 2086.	1.5	12
100	Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 45-55.	4.6	55
101	Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer. <i>Cell Reports Medicine</i> , 2022, 3, 100781.	3.3	15
102	Immunogenicity and Effectiveness of Primary and Booster Vaccine Combination Strategies during Periods of SARS-CoV-2 Delta and Omicron Variants. <i>Vaccines</i> , 2022, 10, 1596.	2.1	1
103	Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study. <i>Lancet Respiratory Medicine</i> ,the, 2023, 11, 176-187.	5.2	17
104	Vaccine-induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	19
106	Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection. <i>Med</i> , 2022, 3, 838-847.e3.	2.2	26
107	The elusive goal of COVID-19 vaccine immunity. <i>Lancet Respiratory Medicine</i> ,the, 2023, 11, 115-117.	5.2	3
108	Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil. <i>Nature Communications</i> , 2022, 13, .	5.8	53
109	The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern. <i>PLoS Pathogens</i> , 2022, 18, e1010882.	2.1	8
110	Rates of COVID-19 Infection Among Healthcare Workers in Designated COVID-19 Wards and General Wards. <i>Journal of Korean Medical Science</i> , 2022, 37, .	1.1	3
111	The Importance of Incorporating At-Home Testing Into SARS-CoV-2 Point Prevalence Estimates: Findings From a US National Cohort, February 2022. <i>JMIR Public Health and Surveillance</i> , 2022, 8, e38196.	1.2	10
114	Factors That Affect the COVID-19 Pandemic in Summer 2022 Compared to Summer 2021. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 12561.	1.2	5
116	Prerequisite for COVID-19 Prediction: A Review on Factors Affecting the Infection Rate. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 12997.	1.2	3
117	Effectiveness of mRNA COVID-19 Vaccine Boosters Against Infection, Hospitalization, and Death: A Target Trial Emulation in the Omicron (B.1.1.529) Variant Era. <i>Annals of Internal Medicine</i> , 2022, 175, 1693-1706.	2.0	25
118	Effectiveness of mRNA Booster Vaccination Against Mild, Moderate, and Severe COVID-19 Caused by the Omicron Variant in a Large, Population-Based, Norwegian Cohort. <i>Journal of Infectious Diseases</i> , 2022, 226, 1924-1933.	1.9	10
119	Covid-19 Vaccine Protection among Children and Adolescents in Qatar. <i>New England Journal of Medicine</i> , 2022, 387, 1865-1876.	13.9	37
123	Multiple Venous and Pulmonary Artery Thrombosis as the Presenting Features of Spontaneously Reversible Nephrotic Syndrome after Exposure to SARS-CoV-2 Virus (Pfizer/BioNTech BNT162b2) Vaccination. <i>Vaccines</i> , 2022, 10, 1888.	2.1	1

#	ARTICLE	IF	CITATIONS
124	Intranasal delivery of a rationally attenuated SARS-CoV-2 is immunogenic and protective in Syrian hamsters. <i>Nature Communications</i> , 2022, 13, .	5.8	11
127	Neutralizing antibodies against SARS-CoV-2 are higher but decline faster in mRNA vaccinees compared to individuals with natural infection. <i>Journal of Travel Medicine</i> , 2022, 29, .	1.4	4
128	Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study. <i>Lancet Microbe</i> , The, 2022, 3, e944-e955.	3.4	34
129	Relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine up to four months post administration in individuals aged 80 years or more in Italy: A retrospective matched cohort study. <i>Vaccine</i> , 2023, 41, 76-84.	1.7	7
130	Antibody response to a third SARS-CoV-2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 0, , .	1.2	3
131	Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland – A multicentre cohort study. <i>PLoS Medicine</i> , 2022, 19, e1004125.	3.9	11
133	Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years. <i>Vaccines</i> , 2022, 10, 1954.	2.1	3
134	Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: real-world study in Jilin Province, China. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	12
135	Vaccine Effect on Household Transmission of Omicron and Delta SARS-CoV-2 Variants. <i>Journal of Korean Medical Science</i> , 2023, 38, .	1.1	4
136	Primary and booster vaccination in reducing severe clinical outcomes associated with Omicron Naïve infection. <i>Journal of Infection and Public Health</i> , 2023, 16, 55-63.	1.9	3
137	Effectiveness of BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and July 2022: a prospective test negative case-control study. <i>Lancet Regional Health - Europe</i> , The, 2023, 25, 100552.	3.0	11
138	The Preventive Role of mRNA Vaccines in Reducing Death among Moderate Omicron-Infected Patients: A Follow-Up Study. <i>Viruses</i> , 2022, 14, 2622.	1.5	2
140	COVID-19 Vaccines: An Updated Overview of Different Platforms. <i>Bioengineering</i> , 2022, 9, 714.	1.6	11
141	Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. <i>Cell Host and Microbe</i> , 2023, 31, 9-17.e3.	5.1	163
142	Impact of Vaccination, Prior Infection, and Therapy on Omicron Infection and Mortality. <i>Journal of Infectious Diseases</i> , 2023, 227, 970-976.	1.9	6
143	Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. <i>Biochemical Society Transactions</i> , 2022, 50, 1643-1658.	1.6	6
144	Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
146	The Epidemiology of Long Coronavirus Disease in US Adults. <i>Clinical Infectious Diseases</i> , 2023, 76, 1636-1645.	2.9	37

#	ARTICLE	IF	CITATIONS
147	One-year dynamics of antibody titers after three doses of SARS-CoV-2 BNT162b2 vaccine. <i>Vaccine</i> , 2022, , .	1.7	4
149	Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 421-434.	4.6	24
150	Immunogenicity against the Omicron Variant after mRNA-Based COVID-19 Booster Vaccination in Medical Students Who Received Two Primary Doses of the mRNA-1273 Vaccine. <i>Vaccines</i> , 2022, 10, 2102.	2.1	1
151	Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression. <i>Vaccines</i> , 2022, 10, 2180.	2.1	16
153	Comparative severity of COVID-19 cases caused by Alpha, Delta or Omicron SARS-CoV-2 variants and its association with vaccination. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2022, , .	0.3	3
154	Effectiveness of COVID-19 Vaccines in Adults with Diabetes Mellitus: A Systematic Review. <i>Vaccines</i> , 2023, 11, 24.	2.1	12
155	Humoral response after a fourth "booster" dose of coronavirus disease 2019 vaccination and outcome of Japan's seventh wave of coronavirus disease 2019 infections in hemodialysis patients: A single-center experience. <i>Therapeutic Apheresis and Dialysis</i> , 2023, 27, 597-598.	0.4	0
156	Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy. <i>Aids</i> , 2023, 37, 709-721.	1.0	9
157	Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar. <i>Journal of Infection and Public Health</i> , 2023, 16, 250-256.	1.9	10
159	Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. <i>Nature Communications</i> , 2023, 14, .	5.8	54
160	Immunogenicity and Safety of the BNT162b2 COVID-19 Vaccine in Patients with Cystic Fibrosis with or without Lung Transplantation. <i>International Journal of Molecular Sciences</i> , 2023, 24, 908.	1.8	6
161	A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model. <i>Journal of Virology</i> , 0, , .	1.5	2
162	Evaluation of mortality attributable to SARS-CoV-2 vaccine administration using national level data from Qatar. <i>Nature Communications</i> , 2023, 14, .	5.8	4
163	Weekly symptom profiles of nonhospitalized individuals infected with SARS-CoV-2 during the Omicron outbreak in Hong Kong: A retrospective observational study from a telemedicine center. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	8
164	Infection by SARS-CoV-2 with alternate frequencies of mRNA vaccine boosting. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	13
165	Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population. <i>Nature Medicine</i> , 2023, 29, 348-357.	15.2	74
166	Covid-19 vaccine effectiveness against general SARS-CoV-2 infection from the omicron variant: A retrospective cohort study. <i>PLOS Global Public Health</i> , 2023, 3, e0001111.	0.5	4
167	Efficacy of Lianhua Qingwen for children with SARS-CoV-2 Omicron infection: A propensity score-matched retrospective cohort study. <i>Phytomedicine</i> , 2023, 111, 154665.	2.3	5

#	ARTICLE	IF	CITATIONS
168	Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines (mRNA) Tj ETQqO 0.0 rgBT /Overlock 10 2022. Open Forum Infectious Diseases, 2023, 10, .	0.4	4
169	Comparative effectiveness of third doses of mRNA-based COVID-19 vaccines in US veterans. Nature Microbiology, 2023, 8, 55-63.	5.9	16
170	Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac. SSRN Electronic Journal, 0, , .	0.4	0
171	Effectiveness of mRNA Vaccine Booster against SARS-CoV-2 Infection and COVID-19 in the Adult Population during the First Three Months of the Omicron Wave in Sicily. Healthcare (Switzerland), 2023, 11, 305.	1.0	3
172	Association between vaccination status and COVID-19-related health outcomes among community-dwelling COVID-19 patients in Nara, Japan. Environmental Health and Preventive Medicine, 2023, 28, 7-7.	1.4	4
174	Neutralizing Efficacy of Encapsulin Nanoparticles against SARS-CoV2 Variants of Concern. Viruses, 2023, 15, 346.	1.5	4
175	Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications. Frontiers in Immunology, 0, 14, .	2.2	14
176	Evaluation of SARSâ€CoVâ€2 antibody levels on hospital admission as a correlate of protection against mortality. Journal of Internal Medicine, 2023, 293, 694-703.	2.7	16
177	Vaccine Effectiveness Against the SARS-CoV-2 B.1.1.529 Omicron Variant in Solid Organ and Islet Transplant Recipients in England: A National Retrospective Cohort Study. Transplantation, 2023, 107, 1124-1135.	0.5	5
179	Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022. Eurosurveillance, 2023, 28, .	3.9	0
180	Adverse Reactions after BNT162b2 Messenger RNA Vaccination for Coronavirus Disease 2019 in Healthcare Workers Compared with Influenza Vaccination. Vaccines, 2023, 11, 363.	2.1	1
181	Factors associated with receipt of COVID-19 vaccination and SARS-CoV-2 seropositivity among healthcare workers in Albania (February 2021â€June 2022): secondary analysis of a prospective cohort study. Lancet Regional Health - Europe, The, 2023, 27, 100584.	3.0	6
182	Comparative severity of COVID-19 cases caused by Alpha, Delta or Omicron SARS-CoV-2 variants and its association with vaccination. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2024, 42, 187-194.	0.2	3
183	Estimation of Vaccine Effectiveness of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-CoV-2 Omicron. JAMA Network Open, 2023, 6, e2254777.	2.8	18
184	SARSâ€CoVâ€2 antibody titers at the time of hospital admission and risk for mortality. Journal of Internal Medicine, 2023, 293, 664-665.	2.7	0
185	Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac. Vaccines, 2023, 11, 356.	2.1	0
186	Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine. Open Forum Infectious Diseases, 2023, 10, .	0.4	0
187	Sustained Myocarditis following Messenger RNA Vaccination against Coronavirus Disease 2019: Relation to Neutralizing Antibody and Amelioration by Low-Dose Booster Vaccination. Journal of Clinical Medicine, 2023, 12, 1421.	1.0	1

#	ARTICLE	IF	CITATIONS
188	Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies. <i>Nature Communications</i> , 2023, 14, .	5.8	87
189	Optimized workplace risk mitigation measures for SARS-CoV-2 in 2022. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
190	The prevalence of SARS-CoV-2 infection and long COVID in U.S. adults during the BA.4/BA.5 surge, June–July 2022. <i>Preventive Medicine</i> , 2023, 169, 107461.	1.6	17
191	Effectiveness of mRNA vaccine against Omicron-related infections in the real world: A systematic review and meta-analysis. <i>American Journal of Infection Control</i> , 2023, 51, 1049-1055.	1.1	4
192	Dynamics of Anti-S IgG Antibodies Titers after the Second Dose of COVID-19 Vaccines in the Manual and Craft Worker Population of Qatar. <i>Vaccines</i> , 2023, 11, 496.	2.1	2
193	Mucosal immunization with Ad5-based vaccines protects Syrian hamsters from challenge with omicron and delta variants of SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
194	A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452. <i>Vaccine</i> , 2023, 41, 2184-2197.	1.7	7
195	Lung tropism in hospitalized patients following infection with SARS-CoV-2 variants from D614G to Omicron BA.2. <i>Communications Medicine</i> , 2023, 3, .	1.9	5
196	Immunisation against COVID-19 in Pregnancy and of Women Planning Pregnancy. <i>Viruses</i> , 2023, 15, 621.	1.5	4
197	Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France. <i>Vaccine</i> , 2023, 41, 2280-2288.	1.7	5
198	Value of Laboratory Indicators in Predicting Pneumonia in Symptomatic COVID-19 Patients Infected with the SARS-CoV-2 Omicron Variant. <i>Infection and Drug Resistance</i> , 0, Volume 16, 1159-1170.	1.1	4
199	Effectiveness of first and second COVID-19 mRNA vaccine monovalent booster doses during a period of circulation of Omicron variant sublineages: December 2021–July 2022. <i>Influenza and Other Respiratory Viruses</i> , 2023, 17, .	1.5	7
200	Effectiveness of mRNA and viral vector vaccines in epidemic period led by different SARS-CoV-2 variants: A systematic review and meta-analysis. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	3
201	Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial. <i>Lancet Respiratory Medicine</i> , 2023, 11, 613-623.	5.2	14
202	Vaccine Effectiveness Against Severe Disease and Death for Patients With COVID-19 During the Delta-Dominant and Omicron-Emerging Periods: A K-COVE Study. <i>Journal of Korean Medical Science</i> , 2023, 38, .	1.1	10
203	Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). <i>Expert Review of Vaccines</i> , 2023, 22, 288-298.	2.0	4
204	Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study. <i>Lancet Infectious Diseases</i> , 2023, 23, 816-827.	4.6	35
206	Distinct platelet crosstalk with adaptive and innate immune cells after adenoviral and mRNA vaccination against SARS-CoV-2. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 1636-1649.	1.9	6

#	ARTICLE	IF	CITATIONS
207	Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	17
208	Prior SARS-CoV-2 infection enhances and reshapes spike protein-specific memory induced by vaccination. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	15
209	Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants. <i>Npj Vaccines</i> , 2023, 8, .	2.9	7
210	Protection against Omicron BA.1/BA.2 severe disease 7 months after BNT162b2 booster. <i>Communications Biology</i> , 2023, 6, .	2.0	3
211	Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies. <i>PLoS ONE</i> , 2023, 18, e0283473.	1.1	2
212	Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers. <i>Nature Communications</i> , 2023, 14, .	5.8	8
213	COVID-19 vaccine antibody responses in community-dwelling adults to 48 weeks post primary vaccine series. <i>IScience</i> , 2023, 26, 106506.	1.9	4
214	Two-Year Cohort Study of SARS-CoV-2, Verona, Italy, 2020-2022. <i>Emerging Infectious Diseases</i> , 2023, 29, 822-825.	2.0	0
215	Assessing the generation of tissue resident memory T cells by vaccines. <i>Nature Reviews Immunology</i> , 2023, 23, 655-665.	10.6	10
216	Lack of association between vaccination rates and excess mortality in Cyprus during the COVID-19 pandemic. <i>Vaccine</i> , 2023, , .	1.7	2
217	Criticism of the HAS Opinion of 21 July 2022 Pertaining the Maintenance of SARS-Cov-2 Vaccine Mandate for Healthcare Workers in France. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
218	Correlates of breakthrough Omicron (B.1.1.529) infections in a prospective cohort of vaccinated patients with rheumatic diseases. <i>Rheumatology International</i> , 2023, 43, 1033-1039.	1.5	3
219	Effectiveness of inactivated COVID-19 vaccines among older adults in Shanghai: retrospective cohort study. <i>Nature Communications</i> , 2023, 14, .	5.8	8
220	Evaluation of anti-nucleocapsid level variation to assess SARS-CoV-2 seroprevalence in a vaccinated population. <i>Infectious Diseases</i> , 2023, 55, 425-430.	1.4	5
221	Immediate and Contributory Causes of Death in Patients Hospitalized with COVID-19. <i>International Journal of Infectious Diseases</i> , 2023, , .	1.5	0
222	Eight-Month Follow-Up After the Third Dose of BNT162b2 Vaccine in Healthcare Workers: The Question of a Fourth Dose. <i>Journal of Korean Medical Science</i> , 2023, 38, .	1.1	0
224	Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial. <i>Journal of Infection</i> , 2023, 87, 18-26.	1.7	7
264	mRNA vaccines in disease prevention and treatment. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	9

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------